Pharmakotherapie von Anorexia nervosa und Bulimia nervosa: State of the Art

M. Greetfeld; U. Cuntz; U. Voderholzer

doi:10.1055/s-0031-1281845

Fortschritte der Neurologie · Psychiatrie, Table of Contents

Fortschr Neurol Psychiatr 2012; 80(1): 9-16
DOI: 10.1055/s-0031-1281845

Übersicht

Pharmakotherapie von Anorexia nervosa und Bulimia nervosa: State of the Art

Pharmacotherapy for Anorexia Nervosa and Bulimia Nervosa

M. Greetfeld

¹Schön Klinik Roseneck, Prien am Chiemsee

,

U. Cuntz

¹Schön Klinik Roseneck, Prien am Chiemsee

,

U. Voderholzer

¹Schön Klinik Roseneck, Prien am Chiemsee

²Abteilung Psychiatrie und Psychotherapie, Universitätsklinikum Freiburg

› Author Affiliations

Abstract

Zusammenfassung

Sowohl für Magersucht (Anorexia nervosa, AN) als auch für Bulimia nervosa (BN), ist Psychotherapie die Therapie der ersten Wahl. In der Praxis werden häufig auch medikamentöse Behandlungen durchgeführt. Der Kliniker steht bei der Auswahl der geeigneten Pharmakotherapie vor Schwierigkeiten (z. B. limitierter Zulassungsstatus von Medikamenten, schwer kalkulierbare Pharmakodynamik bei Untergewicht oder Purgingverhalten, Behandlungsbedarf komorbider Störungen). Die vorliegende Übersicht fasst den gegenwärtigen, leitlinienorientierten Kenntnisstand zur Pharmakotherapie von AN und BN zusammen. Grundsätzlich ist die Studienlage bei der AN noch unzureichend. Es existiert bislang kein Wirksamkeitsnachweis für Antidepressiva und atypische Neuroleptika hinsichtlich einer Gewichtszunahme; letztere können aber bei Gedankenkreisen und Bewegungsdrang hilfreich sein. Bei der BN sind Antidepressiva das medikamentöse Behandlungsverfahren der ersten Wahl. Langzeiteffekte sind allerdings noch unbekannt.

Abstract

Psychotherapy is the treatment of choice for both anorexia nervosa and for bulimia nervosa. However, many patients are also treated by pharmaceutical drugs. For the clinician it is difficult to choose pharmacotherapy, because the drugs may not be licensed, because of pharmacodynamic problems due to underweight or purging behaviour, or because of comorbidity. The present review summarises the current knowledge on pharmacotherapy for anorexia nervosa and bulimia nervosa considering the available guidelines. In general, the knowledge based on studies is insufficient for anorexia nervosa. Up to now, there is no proof of efficacy for any antidepressant or atypical antipsychotic with respect to weight gain; atypical antipsychotics may be helpful for ruminating or excessive motor hyperactivity. For bulimia nervosa antidepressants are the pharmacotherapy of first choice. Long-term effects, however, are still unknown.

Schlüsselwörter

Essstörungen - Anorexia nervosa - Bulimia nervosa - Pharmakotherapie

Key words

eating disorders - anorexia nervosa - bulimia nervosa - pharmacotherapy

Full Text

References

Literatur
1 WHO. Internationale Klassifikation psychischer Störungen. ICD-10 Kapitel V (F). Klinisch-diagnostische Leitlinien. 7. Aufl. Bern: Huber; 2009
2 Practice guideline for the treatment of patients with eating disorders. 3rd. edition American Psychiatric Association (APA); 2006
3 S3-Leitlinie „Diagnostik und Therapie der Essstörungen“. Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF); 2010
4 Currin L, Schmidt U, Treasure J et al. Time trends in eating disorder incidence. Br J Psychiatry 2005; 186: 132-135
5 Fichter MM, Quadflieg N, Hedlund S. Twelve-year course and outcome predictors of anorexia nervosa. Int J Eat Disord 2006; 39: 87-100
6 Fichter MM, Quadflieg N, Hedlund S. Long-term course of binge eating disorder and bulimia nervosa: relevance for nosology and diagnostic criteria. Int J Eat Disord 2008; 41: 577-586
7 Voderholzer U, Hohagen F. Essstörungen (ICD-10 F5). In: Therapie psychischer Erkrankungen: State of the Art 2010/2011. 6. Aufl. Urban & Fischer Verlag/Elsevier GmbH; 2010: 289-302
8 Kaye W. Neurobiology of anorexia and bulimia nervosa. Physiol Behav 2008; 94: 121-135
9 Flament MF, Bissada H, Spettigue W. Evidence-based pharmacotherapy of eating disorders. Int J Neuropsychopharmacol 2011; 18: 1-19
10 Hay PJ, Claudino AM. Clinical psychopharmacology of eating disorders: a research update. Int J Neuropsychopharmacol 2011; 25: 1-14
11 Eating disorders: full guideline (CG9). National Institute for Health and Clinical Excellence (NICE). 2004;
12 Fassino S, Piero A, Tomba E et al. Factors associated with dropout from treatment for eating disorders: a comprehensive literature review. BMC Psychiatry 2009; 9: 67-67
13 Biederman J, Herzog DB, Rivinus TM et al. Amitriptyline in the treatment of anorexia nervosa: a double-blind, plazebo-controlled study. J Clin Psychopharmacol 1985; 5: 10-16
14 Halmi KA, Eckert E, LaDu TJ et al. Anorexia nervosa. Treatment efficacy of cyproheptadine and amitriptyline. Arch Gen Psychiatry 1986; 43: 177-181
15 Attia E, Haiman C, Walsh BT et al. Does fluoxetine augment the inpatient treatment of anorexia nervosa?. Am J Psychiatry 1998; 155: 548-551
16 Fassino S, Leombruni P, Daga G et al. Efficacy of citalopram in anorexia nervosa: a pilot study. Eur Neuropsychopharmacol 2002; 12: 453-459
17 Walsh BT, Kaplan AS, Attia E et al. Fluoxetine after weight restoration in anorexia nervosa: a randomized controlled trial. JAMA 2006; 295: 2605-2612
18 Santonastaso P, Friederici S, Favaro A. Sertraline in the treatment of restricting anorexia nervosa: an open controlled trial. J Child Adolesc Psychopharmacol 2001; 11: 143-150
19 Strober M, Freeman R, DeAntonio M et al. Does adjunctive fluoxetine influence the post-hospital course of restrictor-type anorexia nervosa?. A 24-month prospective, longitudinal followup and comparison with historical controls. Psychopharmacol Bull 1997; 33: 425-431
20 Ruggiero GM, Mauri MC, Omboni AC et al. Nutritional management of anorexic patients with and without fluoxetine: 1-year follow-up. Prog Neuropsychopharmacol Biol Psychiatry 2003; 27: 425-430
21 Kaye WH, Nagata T, Weltzin TE et al. Double-blind plazebo-controlled administration of fluoxetine in restricting- and restricting-purging-type anorexia nervosa. Biol Psychiatry 2001; 49: 644-652
22 Ruggiero GM, Laini V, Mauri MC et al. A single blind comparison of amisulpride, fluoxetine and clomipramine in the treatment of restricting anorectics. Prog Neuropsychopharmacol Biol Psychiatry 2001; 25: 1049-1059
23 Lacey JH, Crisp AH. Hunger, food intake and weight: the impact of clomipramine on a refeeding anorexia nervosa population. Postgrad Med J 1980; 56 (Suppl. 01) 79-85
24 Jaafar NR, Daud TI, Rahman FN et al. Mirtazapine for anorexia nervosa with depression. Aust N Z J Psychiatry 2007; 41: 768-769
25 Safer DL, Darcy AM, Lock J. Use of mirtazapine in an adult with refractory anorexia nervosa and comorbid depression: a case report. Int J Eat Disord 2011; 44: 178-181
26 Hrdlicka M, Beranova I, Zamecnikova R et al. Mirtazapine in the treatment of adolescent anorexia nervosa. Case-control study. Eur Child Adolesc Psychiatry 2008; 17: 187-189
27 Claudino AM, Hay P, Lima MS et al. Antidepressants for anorexia nervosa. Cochrane Database Syst Rev 2006; CD004365
28 Godart NT, Perdereau F, Rein Z et al. Comorbidity studies of eating disorders and mood disorders. Critical review of the literature. J Affect Disord 2007; 97: 37-49
29 Mischoulon D, Eddy KT, Keshaviah A et al. Depression and eating disorders: Treatment and course. J Affect Disord 2010;
30 Ricca V, Mannucci E, Paionni A et al. Venlafaxine versus fluoxetine in the treatment of atypical anorectic outpatients: a preliminary study. Eat Weight Disord 1999; 4: 10-14
31 Meehan KG, Loeb KL, Roberto CA et al. Mood change during weight restoration in patients with anorexia nervosa. Int J Eat Disord 2006; 39: 587-589
32 Barbarich NC, McConaha CW, Gaskill J et al. An open trial of olanzapine in anorexia nervosa. J Clin Psychiatry 2004; 65: 1480-1482
33 Boachie A, Goldfield GS, Spettigue W. Olanzapine use as an adjunctive treatment for hospitalized children with anorexia nervosa: case reports. Int J Eat Disord 2003; 33: 98-103
34 Powers PS, Santana CA, Bannon YS. Olanzapine in the treatment of anorexia nervosa: an open label trial. Int J Eat Disord 2002; 32: 146-154
35 Bissada H, Tasca GA, Barber AM et al. Olanzapine in the treatment of low body weight and obsessive thinking in women with anorexia nervosa: a randomized, double-blind, plazebo-controlled trial. Am J Psychiatry 2008; 165: 1281-1288
36 Brambilla F, Monteleone P, Maj M. Olanzapine-induced weight gain in anorexia nervosa: involvement of leptin and ghrelin secretion?. Psychoneuroendocrinology 2007; 32: 402-406
37 Mondraty N, Birmingham CL, Touyz S et al. Randomized controlled trial of olanzapine in the treatment of cognitions in anorexia nervosa. Australas Psychiatry 2005; 13: 72-75
38 Malina A, Gaskill J, McConaha C et al. Olanzapine treatment of anorexia nervosa: a retrospective study. Int J Eat Disord 2003; 33: 234-237
39 Weizman A, Tyano S, Wijsenbeek H et al. Behavior therapy, pimozide treatment and prolactin secretion in anorexia nervosa. Psychother Psychosom 1985; 43: 136-140
40 Vandereycken W, Pierloot R. Pimozide combined with behavior therapy in the short-term treatment of anorexia nervosa. A double-blind plazebo-controlled cross-over study. Acta Psychiatr Scand 1982; 66: 445-450
41 Vandereycken W. Neuroleptics in the short-term treatment of anorexia nervosa. A double-blind plazebo-controlled study with sulpiride. Br J Psychiatry 1984; 144: 288-292
42 Cassano GB, Miniati M, Pini S et al. Six-month open trial of haloperidol as an adjunctive treatment for anorexia nervosa: a preliminary report. Int J Eat Disord 2003; 33: 172-177
43 Bosanac P, Kurlender S, Norman T et al. An open-label study of quetiapine in anorexia nervosa. Hum Psychopharmacol 2007; 22: 223-230
44 Powers PS, Bannon Y, Eubanks R et al. Quetiapine in anorexia nervosa patients: an open label outpatient pilot study. Int J Eat Disord 2007; 40: 21-26
45 Court A, Mulder C, Kerr M et al. Investigating the effectiveness, safety and tolerability of quetiapine in the treatment of anorexia nervosa in young people: a pilot study. J Psychiatr Res 2010; 44: 1027-1034
46 Trunko ME, Schwartz TA, Duvvuri V et al. Aripiprazole in anorexia nervosa and low-weight bulimia nervosa: case reports. Int J Eat Disord 2011; 44: 269-275
47 Gross H, Ebert MH, Faden VB et al. A double-blind trial of delta 9-tetrahydrocannabinol in primary anorexia nervosa. J Clin Psychopharmacol 1983; 3: 165-171
48 Gross HA, Ebert MH, Faden VB et al. A double-blind controlled trial of lithium carbonate primary anorexia nervosa. J Clin Psychopharmacol 1981; 1: 376-381
49 Birmingham CL, Goldner EM, Bakan R. Controlled trial of zinc supplementation in anorexia nervosa. Int J Eat Disord 1994; 15: 251-255
50 Pope Jr HG, Hudson JI, Jonas JM et al. Bulimia treated with imipramine: a plazebo-controlled, double-blind study. Am J Psychiatry 1983; 140: 554-558
51 Barlow J, Blouin J, Blouin A et al. Treatment of bulimia with desipramine: a double-blind crossover study. Can J Psychiatry 1988; 33: 129-133
52 Sabine EJ, Yonace A, Farrington AJ et al. Bulimia nervosa: a plazebo controlled double-blind therapeutic trial of mianserin. Br J Clin Pharmacol 1983; 15 (Suppl. 02) 195S-202S
53 Goldstein DJ, Wilson MG, Thompson VL et al. Long-term fluoxetine treatment of bulimia nervosa. Fluoxetine Bulimia Nervosa Research Group. Br J Psychiatry 1995; 166: 660-666
54 Fluoxetine Bulimia Nervosa Collaborative Study Group. Fluoxetine in the treatment of bulimia nervosa. A multicenter, plazebo-controlled, double-blind trial. Arch Gen Psychiatry 1992; 49: 139-147
55 Fichter MM, Leibl K, Rief W et al. Fluoxetine versus plazebo: a double-blind study with bulimic inpatients undergoing intensive psychotherapy. Pharmacopsychiatry 1991; 24: 1-7
56 Fichter MM, Leibl C, Kruger R et al. Effects of fluvoxamine on depression, anxiety, and other areas of general psychopathology in bulimia nervosa. Pharmacopsychiatry 1997; 30: 85-92
57 Milano W, Petrella C, Sabatino C et al. Treatment of bulimia nervosa with sertraline: a randomized controlled trial. Adv Ther 2004; 21: 232-237
58 Capasso A, Petrella C, Milano W. Pharmacological profile of SSRIs and SNRIs in the treatment of eating disorders. Curr Clin Pharmacol 2009; 4: 78-83
59 Pope Jr HG , Keck Jr PE , McElroy SL et al. A plazebo-controlled study of trazodone in bulimia nervosa. J Clin Psychopharmacol 1989; 9: 254-259
60 Bacaltchuk J, Hay P. Antidepressants versus plazebo for people with bulimia nervosa. Cochrane Database Syst Rev 2003; CD003391
61 Carruba MO, Cuzzolaro M, Riva L et al. Efficacy and tolerability of moclobemide in bulimia nervosa: a plazebo-controlled trial. Int Clin Psychopharmacol 2001; 16: 27-32
62 Horne RL, Ferguson JM, Pope Jr HG et al. Treatment of bulimia with bupropion: a multicenter controlled trial. J Clin Psychiatry 1988; 49: 262-266
63 Romano SJ, Halmi KA, Sarkar NP et al. A plazebo-controlled study of fluoxetine in continued treatment of bulimia nervosa after successful acute fluoxetine treatment. Am J Psychiatry 2002; 159: 96-102
64 Schmidt U, Cooper PJ, Essers H et al. Fluvoxamine and graded psychotherapy in the treatment of bulimia nervosa: a randomized, double-blind, plazebo-controlled, multicenter study of short-term and long-term pharmacotherapy combined with a stepped care approach to psychotherapy. J Clin Psychopharmacol 2004; 24: 549-552
65 Sysko R, Sha N, Wang Y et al. Early response to antidepressant treatment in bulimia nervosa. Psychol Med 2010; 40: 999-1005
66 Goldstein DJ, Wilson MG, Ascroft RC et al. Effectiveness of fluoxetine therapy in bulimia nervosa regardless of comorbid depression. Int J Eat Disord 1999; 25: 19-27
67 Agras WS, Rossiter EM, Arnow B et al. Pharmacologic and cognitive-behavioral treatment for bulimia nervosa: a controlled comparison. Am J Psychiatry 1992; 149: 82-87
68 Goldbloom DS, Olmsted M, Davis R et al. A randomized controlled trial of fluoxetine and cognitive behavioral therapy for bulimia nervosa: short-term outcome. Behav Res Ther 1997; 35: 803-811
69 Bacaltchuk J, Hay P, Trefiglio R. Antidepressants versus psychological treatments and their combination for bulimia nervosa. Cochrane Database Syst Rev 2001; CD003385
70 Nickel C, Tritt K, Muehlbacher M et al. Topiramate treatment in bulimia nervosa patients: a randomized, double-blind, plazebo-controlled trial. Int J Eat Disord 2005; 38: 295-300
71 Hedges DW, Reimherr FW, Hoopes SP et al. Treatment of bulimia nervosa with topiramate in a randomized, double-blind, plazebo-controlled trial, part 2: improvement in psychiatric measures. J Clin Psychiatry 2003; 64: 1449-1454
72 Hoopes SP, Reimherr FW, Hedges DW et al. Treatment of bulimia nervosa with topiramate in a randomized, double-blind, plazebo-controlled trial, part 1: improvement in binge and purge measures. J Clin Psychiatry 2003; 64: 1335-1341
73 Faris PL, Kim SW, Meller WH et al. Effect of decreasing afferent vagal activity with ondansetron on symptoms of bulimia nervosa: a randomised, double-blind trial. Lancet 2000; 355: 792-797
74 Hsu LK, Clement L, Santhouse R et al. Treatment of bulimia nervosa with lithium carbonate. A controlled study. J Nerv Ment Dis 1991; 179: 351-355